Trials / Completed
CompletedNCT02247154
A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency
A Study of the Safety and Efficacy of an Intravenous Immunoglobulin (Vigam® Liquid) in Patients With Primary or Secondary Antibody Deficiency.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Bio Products Laboratory · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To determine: 1. The safety of Vigam® Liquid in patients with primary or secondary antibody deficiency (PAD or SAD). 2. The efficacy of Vigam® Liquid in patients with primary or secondary antibody deficiency. 3. The half-life of Vigam® Liquid after 4 months of treatment. 4. The subclass and total gammaglobulin concentrations after each infusion of Vigam® Liquid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Vigam® (Human Normal Immunoglobulin) |
Timeline
- Start date
- 1999-04-01
- Primary completion
- 2001-07-01
- First posted
- 2014-09-23
- Last updated
- 2018-02-15
Locations
8 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02247154. Inclusion in this directory is not an endorsement.